May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Whole Body FDG-PET/CT Staging of Ocular Sebaceous Cell Carcinoma
Author Affiliations & Notes
  • J. Shulman
    The New York Eye Cancer Center, New York, New York
  • S. M. Krishna
    The New York Eye Cancer Center, New York, New York
  • K. J. Chin
    The New York Eye Cancer Center, New York, New York
  • M. S. Milner
    The New York Eye and Ear Infirmary, New York, New York
  • P. T. Finger
    The New York Eye Cancer Center, New York, New York
    New York University School of Medicine, New York, New York
  • Footnotes
    Commercial Relationships J. Shulman, None; S.M. Krishna, None; K.J. Chin, None; M.S. Milner, None; P.T. Finger, None.
  • Footnotes
    Support The EyeCare Foundation, Inc., New York City,
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3592. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Shulman, S. M. Krishna, K. J. Chin, M. S. Milner, P. T. Finger; Whole Body FDG-PET/CT Staging of Ocular Sebaceous Cell Carcinoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3592.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To present the first reported use of 18-fluoro-deoxy-glucose (FDG) positron emission tomography / computed radiographic tomography (PET/CT) for staging of ocular sebaceous cell carcinoma.


Two patients with biopsy proven diffuse multi-focal sebaceous cell carcinoma of the conjunctiva and eyelids were evaluated for ocular tumor and distant metastases with whole body FDG PET/CT imaging.


In the first case, whole body PET/CT of sebaceous carcinoma revealed both local ocular uptake as well as metastatic disease in the right submandibular, supraclavicular, mediastinal, and retroperitoneal lymph nodes. In this case, the results of PET/CT assisted in the determination that orbital exenteration surgery was not necessary and that palliative systemic chemotherapy (5-FU and cisplatinum) should be employed. In the second patient with diffuse multifocal sebaceous carcinoma of the conjunctiva and eyelid, whole body PET/CT revealed activity in the ocular adnexa with no evidence of metastatic disease. This patient subsequently underwent topical chemotherapy followed by eyelid resection to preserve her globe and vision. Repeat PET/CT staging at 6 months was negative for metastatic disease.


Whole-body PET/CT was used to combine metabolic information (PET) with anatomic location and shape (CT) to identify local and metastatic ocular sebaceous cell carcinoma. This study suggests that staging of ocular sebaceous carcinoma can be performed using whole body PET/CT with fusion.  

Keywords: oncology • eyelid • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.